


CLAIMS

I claim:

1. A method of treating psoriasis comprising administering to a patient with psoriasis an effective amount of (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol having the formula:



2. The method of claim 1 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered orally.


3. The method of claim 1 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered parenterally.

4. The method of claim 1 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered transdermally.

5. The method of claim 1 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered topically.

6. The method of claim 1 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered in a dosage of from about 0.01 μ g/day to about 100 μ g/day.

7. A method of treating a disease selected from the group consisting of leukemia, colon cancer, breast cancer or prostate cancer comprising administering to a patient with said disease an effective amount of (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol having the formula:



8. The method of claim 7 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered orally.


9. The method of claim 7 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered parenterally.

10. The method of claim 7 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered transdermally.

11. The method of claim 7 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered in a dosage of from about 0.01 μ g/day to about 100 μ g/day.

12. A method of treating an autoimmune disease selected from the group consisting of multiple sclerosis, lupis, diabetes, mellitus, host versus graft reaction, and rejection of organ transplants, comprising administering to a patient with said disease an

effective amount of (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol
5 having the formula:




13. The method of claim 12 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered orally.

14. The method of claim 12 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered parenterally.

15. The method of claim 12 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered transdermally.

16. The method of claim 12 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered in a dosage of from about 0.01 μ g/day to about 100 μ g/day.

17. A method of treating an inflammatory disease selected from the group consisting of rheumatoid arthritis, asthma, and inflammatory bowel diseases, comprising administering to a patient with said disease an effective amount of (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol having the formula:




18. The method of claim 17 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered orally.

19. The method of claim 17 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered parenterally.

20. The method of claim 17 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered transdermally.


21. The method of claim 17 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered in a dosage of from about 0.01 μ g/day to about 100 μ g/day.

22. (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol having the formula:



23. A method of treating a skin condition selected from the group consisting of wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration and insufficient sebum secretion which comprises administering to a patient with said skin condition an effective amount of (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol having the formula:

5



24. The method of claim 23 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered orally.


25. The method of claim 23 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered parenterally.

26. The method of claim 23 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered transdermally.

27. The method of claim 23 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered topically.

28. The method of claim 23 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered in a dosage of from about 0.01 μ g/day to about 100 μ g/day.

29. A method of treating renal osteodystrophy comprising administering to a patient with renal osteodystrophy an effective amount of (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol having the formula:



30. The method of claim 29 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered orally.

31. The method of claim 29 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered parenterally.

32. The method of claim 29 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered transdermally.

33. The method of claim 29 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered in a dosage of from about 0.01 μ g/day to about 100 μ g/day.